{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005403","form_type":"8-K","ticker":"AGPU","cik":"0001446159","company_name":"Axe Compute Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.008748+00:00","generated_at":"2026-05-17T13:04:53.326012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Predictive Oncology Q2 loss $0.22/share; revenue $2.7K; ChemoFx U.S./EU launch expected Q4 2025","bullets":["Loss from continuing ops ~$2.0M; diluted EPS -$0.22 vs -$0.53 YoY.","Revenue $2,682, down 96% from $67,255 due to lower 3D model sales.","Cash $506K; stockholders' deficit $1.65M vs $202K at Dec 31, 2024.","Signed $10M standby equity purchase agreement with Yorkville Advisors.","Advanced ChemoFx market expansion; developed 3D liver models for Labcorp."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005403","json":"https://secwatch.observer/filing/0001171843-25-005403.json","markdown":"https://secwatch.observer/filing/0001171843-25-005403.md","text":"https://secwatch.observer/filing/0001171843-25-005403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446159/000117184325005403/0001171843-25-005403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446159/000117184325005403/f8k_081325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:04:53.326012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}